Physician profile
John Murchison
NPI 1003898289
$5,055.88
in general payments reported to CMS, 2019-2025
32 companies · $2,232 in 2025
The $2,232 reported for 2025 was more than what 86% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $171 · 2021: $300 · 2022: $450 · 2023: $431 · 2024: $676 · 2025: $2,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,311 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,310.80 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $763.96 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Abbvie INC. | $647.57 | 2022-2025 | |
| Allergan, INC. | $352.24 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $329.36 | 2019-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $326.72 | 2024-2025 | Xdemvy |
| Regeneron Pharmaceuticals, INC. | $288.41 | 2021-2025 | Eylea, Eylea Hd |
| Rxsight INC | $243.52 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Genentech, INC. | $233.26 | 2023-2025 | Vabysmo, Susvimo |
| Baxter Healthcare | $203.35 | 2025 | Floseal, Perclot |
| Harrow Eye, LLC | $180.16 | 2024-2025 | Vevye |
| Acera Surgical, INC. | $160.67 | 2025 | Restrata Wound Matrix |
| Mallinckrodt Hospital Products INC. | $133.11 | 2022-2025 | Acthar |
| Axogen | $132.38 | 2023-2024 | Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector |
| Novartis Pharmaceuticals Corporation | $113.53 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $108.67 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.85 | 2019 | |
| Astellas Pharma Global Development | $92.08 | 2025 | Izervay |
| Horizon Therapeutics Plc | $91.79 | 2021 | |
| Eyepoint US, INC. | $82.95 | 2022 | |
| Bausch & Lomb Americas INC. | $70.55 | 2025 | Xipere |
| Rayner Intraocular Lenses Limited | $66.63 | 2022-2025 | Omidria, Rayone Emv, Rayone Aspheric |
| Apellis Pharmaceuticals, INC. | $64.74 | 2025 | Syfovre |
| Biotissue Holdings INC. | $57.90 | 2019-2025 | |
| Carl Zeiss Meditec USA, INC. | $52.34 | 2021-2024 | Iolmaster 700 |
| Ivantis, INC | $30.24 | 2020 | |
| Aerie Pharmaceuticals, INC. | $30.12 | 2019 | |
| Dompe US, INC. | $21.73 | 2019 | |
| Ani Pharmaceuticals, INC. | $20.23 | 2024 | Purified Cortrophin Gel |
| Kala Pharmaceuticals, INC. | $17.05 | 2019 | |
| Shire North American Group INC | $16.00 | 2019 | |
| Genentech USA, INC. | $15.80 | 2019 | |
| Sight Sciences, INC. | $14.97 | 2024 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Murchison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.